17 Sep 2023 AbolerIS Pharma announces €27 million in Series A financing to advance its novel treatment paradigm for autoimmune and inflammatory diseases Member news
15 Sep 2023 argenx announces positive CHMP opinion for subcutaneous efgartigimod for generalized myasthenia gravis Member news
12 Sep 2023 Augustine Therapeutics expands its leadership team and R&D platform, enters regulatory development Member news
08 Sep 2023 SwiftPharma and the Population Council Pursue Agreement to Manufacture Griffithsin Needed for the Development of a Fast-Dissolving Insert for Protection Against HIV Member news
05 Sep 2023 The QbD Group acquires life sciences consultancy Azierta to reinforce its global vigilance services and expand its presence in Spain Member news
04 Sep 2023 Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus Member news
01 Sep 2023 SwiftPharma and AntoXa Corporation sign exclusive collaboration agreement to support the development and commercialization of a plant-made antibody against ricin exposure Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
